Steroid Receptors in Breast Cancer: Sources of Inter-laboratory Variation in Dextran-charcoal Assays

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 1987 Jan 1

PMID 2444291

Citations 9

Authors

S M Thorpe

Affiliations

Soon will be listed here.

Abstract

The presently recognized correlations between various clinical parameters and the concentrations of estrogen and progesterone receptors in breast cancer biopsies are largely based on receptor values obtained using the dextran-coated charcoal (DCC) method. This assay method is highly sensitive to slight changes in assay protocol, and differences in assay methodology may account for the wide variation in proportions of receptor positive patients reported by different centers. A survey of various aspects of the assay method that may lead to reproducible, systematic differences in concentrations of receptor levels is presented; and methods of compensating for or correcting these potential differences are discussed. The following aspects are considered: a) constitution of biopsy tissue, b) method of tissue homogenization, c) absorption of ligands to surfaces, d) inclusion of molybdate in the assay buffer, e) composition of the DCC slurry, and f) handling of samples for liquid scintillation counting. Differences in methods used to homogenize tissue in Europe and the U.S.A. may account for differences observed in the correlation of DCC assay results obtained using the recently-introduced monoclonal ER-EIA technique.

Citing Articles

Breast cancer subtypes and survival in chinese women with operable primary breast cancer.

Li Z, Yao L, Liu Y, Ouyang T, Li J, Wang T Chin J Cancer Res. 2013; 23(2):134-9.

PMID: 23482992 PMC: 3587543. DOI: 10.1007/s11670-011-0134-z.

Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.

Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J J Clin Oncol. 2009; 27(21):3423-9.

PMID: 19487384 PMC: 2717750. DOI: 10.1200/JCO.2008.17.2254.

Comparison of short-term estrogenicity tests for identification of hormone-disrupting chemicals.

Andersen H, Andersson A, Arnold S, Autrup H, Barfoed M, Beresford N Environ Health Perspect. 1999; 107 Suppl 1:89-108.

PMID: 10229711 PMC: 1566352. DOI: 10.1289/ehp.99107s189.

Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue.

Ferrier C, de Witte H, Straatman H, van Tienoven D, van Geloof W, Rietveld F Br J Cancer. 1999; 79(9-10):1534-41.

PMID: 10188903 PMC: 2362713. DOI: 10.1038/sj.bjc.6690245.

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.

Knoop A, Andreasen P, Andersen J, Hansen S, Laenkholm A, Simonsen A Br J Cancer. 1998; 77(6):932-40.

PMID: 9528837 PMC: 2150087. DOI: 10.1038/bjc.1998.154.

References

Jacquemier J, Rolland P, Vague D, LIEUTAUD R, Spitalier J, Martin P . Relationships between steroid receptor and epithelial cell proliferation in benign fibrocystic disease of the breast. Cancer. 1982; 49(12):2534-6. DOI: 10.1002/1097-0142(19820615)49:12<2534::aid-cncr2820491221>3.0.co;2-j. View

Miller L, Tuazon F, Niu E, Sherman M . Human breast tumor estrogen receptor: effects of molybdate and electrophoretic analyses. Endocrinology. 1981; 108(4):1369-78. DOI: 10.1210/endo-108-4-1369. View

Jungblut P, Hughes S, Hughes A, Wagner R . Evaluation of various methods for the assay of cytoplasmic oestrogen receptors in extracts of calf uteri and human breast cancers. Acta Endocrinol (Copenh). 1972; 70(1):185-95. DOI: 10.1530/acta.0.0700185. View

Leclercq G, Bojar H, Goussard J, Nicholson R, Pichon M, PIFFANELLI A . Abbott monoclonal enzyme immunoassay measurement of estrogen receptors in human breast cancer: a European multicenter study. Cancer Res. 1986; 46(8 Suppl):4233s-4236s. View

Peck Jr E, Clark J . Effect of ionic strength on charcoal adsorption assays of receptor-estradiol complexes. Endocrinology. 1977; 101(4):1034-43. DOI: 10.1210/endo-101-4-1034. View

Rose C, Thorpe S, ANDERSEN K, Pedersen B, Mouridsen H, Blichert-Toft M . Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet. 1985; 1(8419):16-9. DOI: 10.1016/s0140-6736(85)90966-3. View

. Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. Eur J Cancer (1965). 1980; 16(11):1513-5. DOI: 10.1016/0014-2964(80)90064-x. View

Martin P, Rolland P, Jacquemier J, Rolland A, TOGA M . Routine analysis of multiple steroid receptors in human breast cancer.--I--Technological features. Biomedicine. 1978; 28(5):278-87. View

Martin P, Rolland P, Jacquemier J, Rolland A, TOGA M . Multiple steroid receptors in human breast cancer. II. Estrogen and progestin receptors in 672 primary tumors. Cancer Chemother Pharmacol. 1979; 2(2):107-13. DOI: 10.1007/BF00254082. View

10.

Clark G, Osborne C, McGuire W . Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol. 1984; 2(10):1102-9. DOI: 10.1200/JCO.1984.2.10.1102. View

11.

Allegra J, Lippman M, Green L, Barlock A, Simon R, Thompson E . Estrogen receptor values in patients with benign breast disease. Cancer. 1979; 44(1):228-31. DOI: 10.1002/1097-0142(197907)44:1<228::aid-cncr2820440137>3.0.co;2-0. View

12.

BRAUNSBERG H . Factors influencing the estimation of oestrogen receptors in human malignant breast tumours. Eur J Cancer (1965). 1975; 11(7):499-507. DOI: 10.1016/0014-2964(75)90152-8. View

13.

Jordan V, Jacobson H, Keenan E . Determination of estrogen receptor in breast cancer using monoclonal antibody technology: results of a multicenter study in the United States. Cancer Res. 1986; 46(8 Suppl):4237s-4240s. View

14.

OXLEY D, Haven G, Wittliff J, Gilbo D . Precision in estrogen and progesterone receptor assays. Results of the first CAP pilot survey. Am J Clin Pathol. 1982; 78(4 Suppl):587-96. View

15.

Garola R, McGuire W . A hydroxylapatite micromethod for measuring estrogen receptor in human breast cancer. Cancer Res. 1978; 38(8):2216-20. View

16.

Krozowski Z, Murphy L . Stabilisation of the cytoplasmic oestrogen receptor by molybdate. J Steroid Biochem. 1981; 14(4):363-6. DOI: 10.1016/0022-4731(81)90155-2. View

17.

Thorpe S, Koenders A . Standardization of steroid receptor assays in human breast cancer--III. Selection of reference material for intra- and inter-laboratory quality control. Eur J Cancer Clin Oncol. 1986; 22(8):939-44. DOI: 10.1016/0277-5379(86)90060-x. View

18.

Koenders A, Thorpe S . Standardization of steroid receptor assays in human breast cancer--II. Samples with low receptor content. Eur J Cancer Clin Oncol. 1983; 19(10):1467-72. DOI: 10.1016/0277-5379(93)90017-y. View

19.

Pichon M, Pallud C, Brunet M, Milgrom E . Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res. 1980; 40(9):3357-60. View

20.

Zava D, Goldhirsch A, ROOS W, Takahashi A, Eppenberger U, Arrenbrecht S . A quality control study to assess the inter-laboratory variability of routine estrogen and progesterone receptor assays. Eur J Cancer Clin Oncol. 1982; 18(8):713-21. DOI: 10.1016/0277-5379(82)90068-2. View